...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of the advanced practitioner in oncology >Predictive and Prognostic Biomarkers and Related Therapies in Non-Small Cell Lung Cancer
【24h】

Predictive and Prognostic Biomarkers and Related Therapies in Non-Small Cell Lung Cancer

机译：非小细胞肺癌预测性和预后生物标志物及相关疗法

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Non-small cell lung cancer (NSCLC) is the leading form of lung carcinoma in the United States. Systemic chemotherapy has remained the mainstay of treatment; however, advances in the identification of driver mutations have allowed the development of therapies that specifically target precise cell processes. These biomarkers have predictive value in determining the likelihood a patient will respond to a certain therapy and prognostic value in determining patient survival independent of therapy received. Common driver mutations found in NSCLC that are reviewed in this article include epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), ROS1, and Kirsten rat sarcoma viral oncogene (KRAS). This article also discusses targeted therapies available for each driver mutation including afatinib, alec-tinib, brigatinib, ceritinib, cri.zotinib, erlotinib, gefitinib, and osimertinib. Upcoming targeted therapies that are currently undergoing clinical trials are explored as well.
机译：非小细胞肺癌（NSCLC）是美国肺癌的主要形式。 全身化疗仍然是治疗的主要支柱; 然而，识别驾驶员突变的进步允许开发特异性靶向精确细胞过程的疗法。 这些生物标志物在确定患者对某种治疗和预后值决定患者存活方面的可能性，这些生物标志物具有预测值。 在本文中审查的NSCLC中发现的常见驾驶员突变包括表皮生长因子受体（EGFR），促进淋巴瘤激酶（ALK），ROS1和Kirsten大鼠肉瘤病毒癌基因（KRAS）。 本文还讨论了可用于每个驾驶员突变的有针对性的治疗，包括AFATINIB，ALEC-TINIB，Brigatinib，Ceritinib，CRI.Zotinib，Erlotinib，Gefitinib和Osimertinib。 探讨了目前正在进行临床试验的有针对性的疗法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号